The research plan of the CRADA is designed to develop a novel AML MRD assay for monitoring the expression of multiple genes that can document the kinetics of minimal residual disease in acute myeloid leukemia during treatment with SELLAS' most advanced product candidate, galinpepimut-S, the Company's WT1 cancer vaccine. Galinpepimut-S is a late clinical-stage cancer immunotherapy being developed to target hematologic cancers and solid tumors, including AML, malignant pleural mesothelioma , multiple myeloma, ovarian cancer, and multiple other cancers.
